Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Theratechnologies ( (TSE:TH) ) has shared an update.
Theratechnologies has received final court approval for its acquisition by Future Pak, with the arrangement expected to be completed by September 25, 2025. This acquisition could impact Theratechnologies’ market positioning and operations, potentially affecting stakeholders such as customers, business partners, and employees.
The most recent analyst rating on (TSE:TH) stock is a Hold with a C$4.50 price target. To see the full list of analyst forecasts on Theratechnologies stock, see the TSE:TH Stock Forecast page.
Spark’s Take on TSE:TH Stock
According to Spark, TipRanks’ AI Analyst, TSE:TH is a Neutral.
Theratechnologies’ overall score is driven by positive corporate events, including a favorable acquisition agreement, which boosts shareholder value. Strong technical indicators also support the stock’s outlook. However, financial performance and valuation challenges, such as negative equity and a lack of profitability, weigh on the score.
To see Spark’s full report on TSE:TH stock, click here.
More about Theratechnologies
Theratechnologies is a specialty biopharmaceutical company focused on the commercialization of innovative therapies aimed at redefining standards of care. The company is publicly traded on the TSX and NASDAQ.
Average Trading Volume: 50,192
Technical Sentiment Signal: Hold
Current Market Cap: C$207.8M
See more data about TH stock on TipRanks’ Stock Analysis page.